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ABSTRACT
HETEROCYCLIC AMINES AND ARYLAMINE N-ACETYLTRANSFERASE 2
POLYMORPHISM IN PATHOGENESIS OF INSULIN RESISTANCE
Kennedy M. Walls
April 15, 2021

Heterocyclic amines (HCAs) are formed when cooking meats at high
temperatures or for long periods of time, and their major metabolic pathway
includes hepatic N‑hydroxylation by CYP1A2 followed by O-acetylation by Nacetyltransferase 2 (NAT2). NAT2 is a highly polymorphic gene involved in
metabolism of drugs and xenobiotics, and its single nucleotide polymorphisms
(SNPs) produce phenotypes characterized as slow, intermediate, or rapid
acetylator. Recent studies have documented associations between HCAs and
insulin resistance and between certain NAT2 phenotypes and insulin resistance.
In this study, we demonstrated that NAT2 activity and exposure to certain HCAs
may alter cellular glucose and lipid homeostasis. Additionally, these results
demonstrate changes in sensitivity to insulin following exposure to some HCAs.
These findings are significant because they indicate a genetic component (NAT2
polymorphism) and an environmental component (dietary HCA exposure via
consumption of cooked meat) in the pathogenesis of insulin resistance in
hepatocytes of human origin.
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INTRODUCTION
Arylamine N-acetyltransferases (NATs)
Arylamine N-acetyltransferases (NATs) are enzymes that metabolize
xenobiotics and drugs, and they are known to play a role in detoxification of
many compounds [1]. Specifically, they add an acetyl group from acetyl
coenzyme A (CoA) to arylamines and arylhydrazines, which may detoxify or
bioactivate the compound. Two NAT genes (NAT1 and NAT2) have been
identified and characterized in humans. NAT1 and NAT2 are similar in structure,
but they differ in substrate selectivity and physiological function [2]. For example,
NAT1 demonstrates an affinity for p-aminobenzoic acid (PABA), and NAT2
demonstrates affinity for sulfamethazine [4]. NAT1 is expressed ubiquitously,
while NAT2 expression is restricted to the liver and gastrointestinal tract [8, 9].
The importance of NAT2’s substrate selectivity and organ-specific expression will
be further discussed in later sections.
NAT1 and NAT2 function as catalysts for both N-acetylation and Oacetylation of drugs, aromatic amines, and heterocyclic amines. NAT2 catalyzes
N-acetylation of drugs like sulfamethazine, hydralazine and dapsone, and this is
usually a deactivation [5]. Following oxidation by cytochrome P450 (CYP450),
NAT2 catalyzes O-acetylation of heterocyclic amines like 2-amino-1-methyl-6phenylimidazo[4,5-b]pyridine (PhIP), 2-amino-3,4-dimethylimidazo[4,5-f]quinoline
1

(MeIQ), and 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) found in
cooked meats, and this is usually an activation process [6].

NATs and metabolism
NATs catalyze both N-acetylation and O-acetylation of drugs, aromatic
amines, and heterocyclic amines. Figure 1 illustrates the reaction pathways
undergone by aromatic and heterocyclic amines [34]. N-conjugation of NATs,
UDP-glucuronosyltransferases (UGTs), or sulfotransferases (SULTs) produces
non-toxic, stable N-acetates, N-glucuronides, and N-sulfates, respectively. In
contrast, N-oxidation of arylamines or N-acetamides, mediated by
cytochrome P450 1A2 (CYP1A2) or by prostaglandin H synthase (PHS)
peroxidase, is a vital step in metabolic activation, generating more reactive
hydroxylamines or hydroxamic acids [35, 36]. Further N-acetylation, Oacetylation and intramolecular N,O-acetyltransfer alters levels of chemically
unstable acetoxy esters and N-acetyl-acetoxy esters, which are considered the
ultimate carcinogens that will spontaneously decompose to electrophilic DNA- or
protein-binding nitrenium ions [37].
In addition to NAT’s ability to catalyze acetyl CoA-dependent conjugation on
nitrogen atoms to produce arylamides and hydrazides, NATs can also
mediate O-acetylation (OAT) and, to a lesser extent, N,O-acetyltransfer (NOAT)
reactions, as demonstrated in Figure 1 below [38]. SULTs and UGTs can also
biotransform hydroxylamines and hydroxamic acids formed by NAT/CYP1A2 into
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sulfate or glucuronide esters that decompose to nitrenium ions [39, 40]. Lastly,
microsomal deacetylases (DAC) can reverse acetylation reactions by influencing
levels of substrates for activating pathways. Tumorigenicity of 2acetylaminofluorene (AAF) may require its deacetylation to the arylamine [41],
which is then presumably activated by pathways previously described.

Figure 1. Pathways of arylamine activation and detoxification. Adapted from
[34].
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To provide an example of NAT2 metabolism, NAT2’s N-acetylation of
aromatic amines like 4-aminobiphenyl (ABP) is a detoxification process. Nacetylation competes with P450-catalyzed N-hydroxylation followed by Oacetylation of N-hydroxy-amine (catalyzed by NAT2), which generates acetoxyderivatives that are highly unstable. This leads to the formation of arylnitrenium
ions that bind to DNA, resulting in mutagenesis and carcinogenesis [18].
Subsequently, NAT allelic variations producing various acetylator phenotypes
impact the extent of these reactions’ effects (see discussions below).

NAT Single Nucleotide Polymorphisms
Both NAT1 and NAT2 exhibit single nucleotide polymorphisms (SNPs),
and NAT2 genotypic variants result in slow, intermediate, and rapid acetylator
phenotypes [14, 15]. SNPs occur when a DNA sequence variation occurs due to
a single nucleotide substitution, producing varying alleles within a locus. For any
given SNP, the SNP can occur in a coding region but not result in a change in
amino acid; it can occur in a coding region and result in an amino acid change; it
can occur in a regulatory region resulting in a change in gene expression; or it
can occur in a region between genes [3]. In the context of NAT2 SNPs discussed
here, these SNPs occur in the coding region of the gene, resulting in amino acid
changes and thus generating different alleles that produce slow, intermediate, or
rapid phenotypes [3].
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There are 28 NAT1 alleles and 108 NAT2 alleles, and allelic frequencies differ
among different populations [10,11]. As mentioned, these SNPs are associated
with varying enzymatic activity and stability, which will be further described in the
following sections [12-14]. To mention some of the more common NAT2 alleles,
NAT2*4 makes up 20–25% of alleles in the population study and is thus often
considered the reference allele, and this is a rapid acetylator phenotype. The
reference allele occurs at a somewhat higher frequency in African Americans
(36–41%) and Hispanics (41%) [27, 28]. Reference allele frequency is highest in
Asians (50% in Chinese and 70% in Japanese) [29-33]. The effects of the rapid
acetylator phenotype of this reference allele will be discussed in the following
section.
An additional frequent NAT2 allele, NAT2*5 and its subtypes, were most
frequent among Caucasians (44%), Gabonese (41%), Hispanics, and those of
African descent (25–27%) [26]. This variant is associated with the slow
acetylation phenotype, in contrast to the reference allele, which generates a rapid
acetylator phenotype. NAT2*6 was distributed evenly across ethnic groups, while
NAT2*7 was more prevalent among Asians. Although only a select few of the
NAT2 allelic variation have been mentioned here, it should be noted that slow
acetylator phenotype is likely not homogeneous, but rather that multiple slow
acetylator phenotypes exist, and these result from different mechanisms inferred
by various SNPs and haplotypes [14]. Thus, there are varying degrees of slow
acetylation within NAT2 polymorphisms.

5

NAT2 SNPs and drug toxicity or cancer risk
Increased risk for drug toxicity and cancer are associated with different NAT2
genotypes and phenotypes [15]. For example, people with the slow NAT2
phenotype have an increased risk of isoniazid-induced liver injury relative to
those with the rapid NAT2 phenotype [16]. Isoniazid is a drug used for the
treatment and prevention of tuberculosis, but treatment had frequently been
compromised by isoniazid-induced hepatotoxicity and liver failure [95]. A
previous study found that the incidence of isoniazid-induced hepatotoxicity
differed among rapid (2.9%), intermediate (9.8%), and slow (22%) NAT2
acetylators [95]. Slow acetylators are significantly more likely to experience
hepatotoxicity from isoniazid treatment for tuberculosis than rapid acetylators
because slow acetylators retain a higher plasma concentration of the drug for an
extended time [96].
Additionally, carriers of the slow acetylator genotype are correlated with
greater adverse health responses after hydralazine treatment relative to rapid
acetylators. Hydralazine is indicated in treatment of chronic hypertension, shortterm therapy of pregnancy-induced hypertension and eclampsia, and in therapy
of hypertensive crisis [97,98]. A rare side effect of hydralazine, a systemic lupus
erythematosus (SLE)-like syndrome, has been observed and can have serious
adverse health consequences. Hydralazine treatment for hypertension is
modified by acetylator phenotype following oral administration [99], and there is
substantial evidence supporting a correlation between NAT2 acetylator
phenotype or genotype and urine and plasma hydralazine concentrations. Like
6

the previously discussed drug isoniazid, slow acetylators are more likely to
experience adverse effects of hydralazine because they maintain higher plasma
concentrations of the drug for a longer period, and thus NAT2 genotype should
be considered when dosing hydralazine.
In addition to alterations in drug toxicity, both rapid and slow NAT2 acetylator
phenotypes have been associated with increased risk of cancer in different target
organs following arylamine exposure [21]. Rapid acetylators detoxify aromatic
amines to a greater extent than slow acetylators via N-acetylation so they may be
excreted from the body more quickly. However, following N-oxidation, the
metabolites can undergo bioactivation via the O-acetylation pathway. The Oacetylation pathway often leads to formation of arylnitrenium ions and DNA
adducts, then carcinogenesis if DNA cannot be repaired. For this reason, slow
NAT2 acetylation has been associated with higher risk of developing urinary
bladder cancer due to decreased ability to detoxify aromatic amines by Nacetylation [19, 20].
In contrast to urinary bladder cancer, the risk of colorectal cancer from welldone cooked meat was higher among rapid NAT2 acetylators compared to slow
acetylators resulting from increased rate of metabolism of heterocyclic amines
(HCAs), carcinogens produced when cooking meat at high temperatures or until
well-done [22-25]. Additionally, rapid acetylators are more prone to liver cancers
following exposure to carcinogenic aromatic amines [35, 38, 39]. To elaborate on
this paradoxical phenomenon, as mentioned previously, CYP450 mediates Nhydroxylation followed by NAT2 O-acetylation of aromatic amines, resulting in a
7

carcinogenic metabolite. Since this metabolic process occurs in the liver, rapid
acetylators are at greater risk of developing liver cancers [110]. However, in the
case of urinary bladder cancer, N-hydroxylated aromatic amines exit the liver,
unaltered by slow NAT2 acetylation, and reach the bladder, where DNA adducts
are formed following an acid-catalyzed reaction with urothelial DNA [8].
Therefore, rapid NAT2 acetylation increases risk of liver cancer, while slow NAT2
acetylation increases risk of urinary bladder cancer. These data indicate the
association of cancer risk with NAT2 phenotype may be exposure and organ
specific.

Heterocyclic Amines (HCAs)
HCA Structures and Classifications
Heterocyclic amines (HCAs) are polycyclic aromatic molecules and known
mutagens [42]. They are primarily formed in muscle foods including meats and
fish, which provide precursors like creatinine, amino acids, and aldehydes [4345]. Cooking meats at high temperatures and for long periods of time including
frying, grilling, and roasting cooking methods substantially enhance HCA
formation [46-48].
More than 25 HCAs have been isolated from food samples and their
structures defined, some of which will be described further in the following
section [49]. All HCAs contain at least one aromatic structure and one
8

heterocyclic structure, and most of them contain an exocyclic amino group. The
five-membered heterocyclic aromatic ring of one class of HCAs, the aminocarbolines, is wedged between two six-membered aromatic rings. In contrast,
another class of HCAs, aminoimidazo-azaarenes (AIAs), have an N-attached
methyl group at the imidazole ring. Amino-carbolines, instead, either lack a
methyl group entirely, or the methyl group is attached to a six-membered ring.
Formation of different classes of mutagens from proteinaceous foods is
determined by the critical heating temperature of 300 degrees Celsius [50].
Protein pyrolysates form above 300 °C, and these are characterized as 2-aminopyridine-mutagens, also known as amino-carbolines [51, 52]. Those formed
below 300 °C are considered 2-amino-imidazole-type mutagens, also known as
aminoimidazo-azaarenes (AIAs) [53]. Pyrolytic mutagens can be further divided
into five groups, including pyridoindoles, pyridoimidazoles, phenylpyridines,
tetraazafluoranthrene, and benzimidazole. AIAs are divided further into three
groups, including IQ, 2-amino-3-methyl-imidazo[4,5-f]quinoxaline (IQx), and
imidazopyridine.
An additional method of classifying HCAs includes polarity. Polar HCAs
include the IQ, IQx-type, and imidazopyridine type (AIAs), while nonpolar HCAs
have a common pyridoindole or dipyridoimidazole moiety [54]. Polar HCAs are
formed from amino acids, carbohydrates, and creatinine when a temperature
between 150 and 250 °C is reached. Non-polar HCAs form at higher
temperatures and are usually assigned as pyrolysis products of the amino acids
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[53]. Figures 2 shows structures of common HCAs that are found most frequently
in meat and known to be carcinogenic.

MeIQ

PhIP

IQ

MeIQx

IQx

Figure 2. Structures of common HCAs. Adapted from [42].

Formation of HCAs
Formation of HCAs is a series of complex chemical reactions. The
browning reaction was proposed by Maillard to account for the brown pigments
and polymers produced from the reaction of the amino group of an amino acid
and the carbonyl group of a sugar [16]. The Maillard reaction encompasses a
network of reactions, including the formation of pyrazines, quinoxalines, and
pyrido[3,4-d]imidazoles, which are involved in the formation of HCAs [46-48].

10

Formation of amino-carbolines
Amino acids or proteins are the precursors of amino-carbolines, and
creatinine is not required for their formation. Therefore, they can be formed in
foods originating from both animals and plants [43]. However, creatinine may
function as an additional source of structural fragments. Free radical reactions
occurring within drastic thermal environments is the suggested pathway for
producing reactive fragments in amino-carbolines [56]. However, this hypothesis
has yet to be fully investigated due to difficult manipulation of high temperatures
required for experimental setups.

Formation of aminoimidazole-azaarenes
AIAs can be responsible for most of the mutagenic activity in cooked
foods, especially in Western diets [57]. IQ- and IQx-type HCAs (structures found
in Figure 2 above) and their methylated forms are likely formed from creatinine,
sugars, free amino acids, and dipeptides through Maillard reaction and Strecker
degradation upon heating [44, 58].
Creatinine was determined to be important for HCA formation because
HCA yield was increased with the addition of creatinine to the surface of meat
prior to frying it [59]. It was demonstrated that cyclization and water elimination of
creatinine formed the amino-imidazo structure of IQ and IQx, and the Maillard
reaction between amino acids and hexose formed the Strecker degradation
products like pyridines or pyrazines, which formed the remainder of the molecule,
11

likely by aldol condensation [43, 61]. While the reaction is favored at temperature
above 100 °C, pyrazine and pyridine yield from Maillard reaction and Strecker
degradation is still low [46]. This phenomenon was considered a factor for low
HCA yield in foods and common model systems, making it difficult to investigate
AIAs [60].

Metabolism of HCAs and cancer
Meat consumption has been associated with increased risk of many
common cancers, including prostate, lung, breast, and colon cancer [100-103].
Genetic variation in NAT2 has been suggested to modify the association of meat
intake with some cancers through its influence on metabolism of HCAs [103].
Thus, epidemiological studies have reported inconsistent associations between
dietary HCA intake via meat consumption and increased cancer risk, as NAT2
allelic variations occur naturally in the sampled human population.
Despite inconsistent epidemiological reports, HCAs are highly mutagenic
in vitro and in vivo [104]. Additionally, when HCAs were fed in the diet, rodents
developed cancers in many organs, including the colon, breast, and prostate,
and one HCA produced hepatomas in monkeys [104]. Many HCAs require
metabolic activation to result in carcinogenesis. The initial step of HCA
metabolism and activation is the generation of N-hydroxy-HCA derivatives, and
this is catalyzed by cytochrome P450, mainly isoenzyme CYP1A2. Further
metabolism and activation is carried out by NAT2 and SULTs, which catalyze
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esterification of N-hydroxy-HCAs, as previously described in the NATs
metabolism section. The resulting products of these reactions are highly
genotoxic and capable of direct interaction with DNA by adduct formation. HCADNA adducts can cause errors in DNA replication and result in mutations, which,
when not repaired, may contribute to carcinogenesis. In contrast, UDPglucuronosyltransferases and glutathione S-transferases are enzymes involved
in detoxification of HCAs [103 – 105]. Balance between activation and
detoxication processes of HCAs, together with genetically determined differences
in HCA metabolism (from NAT2 SNPs), are crucial for the understanding of HCAdependent cancer risk among individuals [105].

Insulin
Insulin is an endocrine peptide hormone that binds plasma membranebound receptors in target cells to orchestrate an anabolic response to nutrient
availability [64]. Insulin is made in the pancreas and secreted from cells called
the Islets of Langerhans. These cells release a small amount of insulin into the
body continuously and release surges of insulin in response to a rise in the blood
glucose level.
Insulin’s role in glucose homeostasis is characterized by insulin’s direct
effects on skeletal muscle, liver, and white adipocytes. In skeletal muscle, insulin
promotes glucose uptake by increasing glucose transport and glycogen
13

synthesis. In the liver, insulin stimulates glycogen synthesis, increases lipogenic
gene expression, and decreases gluconeogenic gene expression. In white
adipocyte tissue, insulin suppresses lipolysis and increases glucose transport
and lipogenesis [64].

Signaling Pathways
There are 2 known insulin-signaling pathways, and they are presented in
Figure 3 below. These pathways are activated by insulin binding to the insulin
receptor (labeled as IR) at the plasma membrane. Insulin/receptor interaction
activates an intrinsic tyrosine protein kinase, which auto-phosphorylates the
receptor and downstream substrates. In the main pathway, proteins known as IR
substrates (IRS) are the immediate downstream substrates, which activate a
cascade of serine-protein kinases [67, 68]. Akt (protein kinase B) is a major
division point with numerous downstream substrates that lead to a variety of
physiological functions like regulation of energy homeostasis [69], and this
pathway will be discussed further in the following sections. The alternate pathway
(‘‘ras/mitogen-activated protein kinase’’) is a serine-protein kinase cascade as
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well, and this pathway regulates transcription, cell growth and differentiation, and
protein synthesis [69, 70].

Figure 3. Two insulin signaling pathways mediate actions of insulin.
Adapted from [64].

Metabolic Syndrome and Insulin Resistance
Metabolic syndrome is clinically defined by having at least 3 of the
following conditions: hypertension, elevated fasting blood sugar, obesity, low
high-density lipoprotein cholesterol, and elevated triglycerides [71]. An individual
with metabolic syndrome is at an increased risk of complications including
atherosclerosis, type II diabetes mellitus, heart attack, kidney disease, fatty liver,
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vascular disease, and stroke [72, 73]. Many have argued that the underlying
etiology of metabolic syndrome could be insulin resistance [73, 74].
When higher insulin levels are required to achieve the same glucoselowering response previously described, a subject is considered insulin resistant.
Plasma lipids, hormones and adipokines, and their respective signaling pathways
regulate insulin sensitivity [79,80], and pathological resistance to insulin (or
lowered insulin sensitivity) develops through multifaceted interactions of
genotype and lifestyle (including exercise habits and diet) [75-78].
Our understanding of the physiology of insulin resistance largely relates to
defective insulin action at target cells. However, when insulin resistance affiliated
with human type II diabetes was shown to involve both a right-shifted doseresponse curve to insulin and a decreased overall maximum insulin response, it
was inferred that both receptor and “post-receptor” (insulin signal transduction)
defects contribute to insulin resistance [75].
The pathophysiology of insulin resistance in skeletal muscle is well
described and can be found in reference texts [64]. For the purposes of this text,
we will instead focus on the pathophysiology of hepatic insulin resistance.

Selective Hepatic Insulin Resistance
The liver plays a crucial role in systemic regulation of glucose and lipid
metabolism and aberrant hepatic insulin action is thought to be a primary factor
in insulin resistance [89]. In individuals with a normal physiologic fasting state,
16

high glucagon-to-insulin ratio will decrease glucose consumption and shift the
liver into glucose production by consuming stored glycogen (glycogenolysis) and
from glucogenic precursors (gluconeogenesis) [90]. Following a meal, decreased
glucagon and increased insulin levels signal the liver to increase glucose
consumption, stop glucose production, and store excess nutrients in the form of
glycogen and lipids [91]. In obese individuals or those with pathological insulin
resistance, insulin fails to regulate hepatic metabolism, leading to excess
production of glucose despite accelerated rates of lipid synthesis. This condition
is known as selective hepatic insulin resistance [92].

Hepatic Insulin Signaling and Lipid Metabolism
As previously mentioned, evidence has indicated that the
phosphoinositide 3-phosphate kinase (PI3K)/Akt pathway is the primary signaling
pathway that mediates insulin’s effects on anabolic metabolism [93]. Figure 4
models the primary insulin signaling pathway in hepatocytes.

17

Figure 4. PI3K/Akt signaling in hepatocytes. Adapted from [89].

Insulin binds to the insulin receptor on the surface of the liver following a
meal. The receptor recruits and activates IRS, which then activates PI3K [94].
PI3K phosphorylates PIP2 into PIP3 in a process that is opposed by PTEN. PIP3
activates 3-phosphoinositide-dependent protein kinase 1 (PDK1), which
phosphorylates Akt at Thr308. mTORC2 also phosphorylates Akt at Ser473 to
fully activate Akt. Various pathways for controlling glucose and lipid homeostasis
branch out from Akt. Glycogen synthesis is induced through Akt inhibition of
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GSK3. Akt can also promote glycogen independent of GSK3 via activation of
GYS2 by glucose-6-phosphate (G6P). Akt inhibition of TSC activates mTORC1,
which then activates SREBP1c and GCK, resulting in phosphorylation of glucose
to G6P. G6P feeds into glycolysis and glycogen synthesis. Additionally, G6P
activates ChREBP, which activates lipogenesis along with SREBP1c. Akt inhibits
FOXO1, causing inhibition of gluconeogenesis by suppressing expression of the
proteins, such as glucose-6-phosphatase (G6PC) and phosphoenolpyruvate
carboxykinase 1 (PCK1). Free fatty acids (FFAs) can also promote
gluconeogenesis and be taken up by the liver and converted to acetyl-CoA,
which activates pyruvate carboxylase and contributes to insulin resistance [89].

Mechanisms of Hepatic Insulin Resistance
Insulin orchestrates a switch from glucose production to glucose uptake in
the liver. This involves suppression of gluconeogenesis and glycogenolysis and
the activation of glycogen synthesis. Suppression of gluconeogenesis involves
acute and chronic processes. Rates of hepatic gluconeogenesis are increased in
type II diabetes and are the cause of fasting hyperglycemia that defines the
disease [119]. Chronic suppression of gluconeogenesis by insulin, better
observed in fasting-refeeding studies than acute insulin stimulation studies, is a
direct hepatocellular effect mediated by inhibition of the FOXO transcription
factors, especially FOXO1.
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Removal of the hepatic insulin receptor is associated with unrestricted
FOXO1 activity, which is required to drive pathological gluconeogenesis [119].
This phenotype is also seen in mice with severe hepatic insulin resistance
resulting from removal of hepatic Irs1 and Irs2, in which Foxo1 deletion
normalizes glucose tolerance [120]. Mouse models of hepatic insulin resistance,
like ob/ob and lipodystrophic mice, display increased G6pc expression, indicating
increased FOXO1 activity [121]. However, hepatic insulin resistance of fat-fed
rats is not accompanied by alterations in gluconeogenic enzyme content, arguing
against a role for FOXO1-driven gluconeogenic gene transcription in genetically
normal rodents [122]. Reducing hepatic Pck1 expression by 90% in mice caused
only a ~40% reduction in gluconeogenic flux, suggesting that fluctuations in Pck1
expression exert limited control over gluconeogenesis [123]. Lastly, a study of
humans with type II diabetes found no increase in the hepatic expression of
FOXO1 targets G6PC and PCK1, despite fasting hyperglycemia [124]. Thus,
depression of FOXO1 can drive pathological gluconeogenesis in rodents, but
there is no strong evidence that this is a functional mechanism for fasting
hyperglycemia in typical human hepatic insulin resistance. The complex control
of hepatic gluconeogenesis indicates transcriptionally mediated increases in
gluconeogenic capacity may not be sufficient to drive gluconeogenesis in
genetically normal subjects. Therefore, increased hepatic gluconeogenesis of
humans with type II diabetes is a complex and poorly understand phenomenon
[64].
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Consumption of Cooked Meat Associated with Insulin Resistance
Heterocyclic amines (HCAs), such as 2-amino-3,4dimethylimidazo[4,5-f]quinoline (MeIQ) and 2-amino-1-methyl-6phenylimidazo[4,5-b]pyridine (PhIP), represent a group of compounds that are
mutagenic and are known human carcinogens [42 – 45]. HCAs are formed via
condensation of creatinine with amino acids when meats are cooked at high
temperatures or for long periods of time [42]. When ingested, HCAs are
absorbed and rapidly distributed. The major metabolic pathway for HCAs
includes hepatic N-hydroxylation by CYP1A2 followed by O-acetylation by
arylamine N-acetyltransferase 2 (NAT2) [21]. This leads to formation of
arylnitrenium ion, which results in DNA damage. Previously, studies on HCAs
and exposure via cooked meat have focused on their carcinogenic potential and
association to common cancers [109]. Recently, an epidemiological study found
a novel link between HCA exposure via cooked meat consumption and insulin
resistance [111]. High HCA intake was associated with increased prevalence of
insulin resistance, even after the multivariate analysis was adjusted for saturated
fatty acid and cholesterol intake. However, this epidemiological association has
not yet been validated in cell or animal models.

NAT2 and Insulin Resistance
Arylamine N-acetyltransferase 2 (NAT2) is a highly polymorphic gene that
catalyzes metabolism of arylamines, including HCAs. NAT2 plays key roles in
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detoxification or activation of carcinogenic arylamines and xenobiotics by
catalyzing acetyl coA-dependent biotransformation of arylamines to Narylacetamides [18]. Individuals can be categorized as rapid, intermediate or
slow acetylators according to their combinations of NAT2 alleles, and NAT2
phenotype has been shown to influence metabolism, and thus the efficacy and
toxicity, of arylamine drugs such as sulfamethazine [2]. NAT2 acetylator
phenotype is associated with increased risk for colorectal cancer following
exposure to HCAs [22 – 24].
Recently, certain genetic variants/polymorphisms of NAT2 have been
linked to insulin resistance, high serum triglyceride, and coronary artery disease
as well as high fasting plasma glucose level [112 – 116]. Analysis of Nat1knockout (homolog of human NAT2) mice revealed that Nat1 deficiency leads to
development of insulin resistance and metabolic defects at the systemic level,
supporting the previously unrecognized role of NAT2 in regulating metabolism
and insulin sensitivity [117 – 118]. However, it is currently unknown how NAT2
influences cellular metabolism and insulin sensitivity.
With newly documented associations between dietary HCA intake and
insulin resistance and between NAT2 polymorphisms and insulin resistance, it is
important we explore the novel link between HCA exposure to pathogenesis of
insulin resistance in cell culture and animal models, and that we investigate the
role of NAT2-mediated metabolism in this process. In the current study, we will
analyze effects of HCAs and NAT2 phenotypes on insulin sensitivity in
hepatocytes of human origin. Our results indicate that HCAs may directly induce
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insulin resistance in human hepatocytes, and that NAT2 phenotype may impact
sensitivity to insulin in human hepatocytes.
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MATERIALS AND METHODS
Source and Processing of Cryopreserved human hepatocytes
Cryopreserved human hepatocytes were obtained from BioIVT and were stored
in liquid nitrogen until use. Hepatocyte samples were collected from consenting
donors under IRB approved protocols at the FDA licensed donor center at BioIVT
(http://www.bioivt.com/). Hepatocytes were prepared from fresh human tissue
and were isolated and frozen within 24 hours of organ removal. The hepatocytes
are human transplant rejected and tested negative for hepatitis B and C and HIV
1 and 2. Hepatocytes were thawed according to the manufacturer’s instructions
once removed from liquid nitrogen by warming a vial of the hepatocytes at 37 °C
for 90 seconds and suspending them in InVitroGRO HT medium (BioIVT,
Baltimore, MD, USA) containing 1 mL TORPEDO™ Antibiotic Mix (BioIVT,
Baltimore, MD, USA) per 45 mL media. Hepatocytes were then plated on
Biocoat® collagen coated plates and remained cultured in this medium while
incubated in humidified air (95%) and carbon dioxide (CO2, 5%) conditions at 37
°C.
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HepG2 cell culture
HepG2 cells were purchased from American Type Culture Collection (ATCC,
ATCC® HB-8065™, Rockville, MD, USA). HepG2 was originally derived from a
liver hepatocellular carcinoma in a male adolescent. The HepG2 cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, Carlsbad, CA,
USA) containing 10% fetal bovine serum (FBS, Gibco), 5.5 mM D-glucose, 1 mM
pyruvate, and 4 mM L-glutamine, and were kept in an incubator with a humidified
air (95%) and carbon dioxide (CO2, 5%) condition at 37 °C.

Cytotoxicity assay
For the cytotoxicity assay, HepG2 cells were treated in indicated compounds
(MeIQ and PhIP) at the indicated concentrations (0, 0.1, 10, 100 µM) for 3 days
in complete media. alamarBlue™ assay was used to measure cell viability.

Generating NAT2 small-hairpin-loop RNA (shRNA) lentivirus
Initially, we screened 8 different shRNA candidates for NAT2 transcript, and the
top two candidates (shRNA4 and shRNA7) were selected for present studies.
The target sequences for the shRNAs are the following: 5’GCTTGAACCTCGAACAATT-3’ for shRNA4; and 5’GCAGACGTCTCCAACATCT-3’ for shRNA7. The target sequence for control
shRNA was 5’-ACTACCGTTGTTATAGGTG-3,’ which does not match any
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known gene transcripts. The templates for the corresponding shRNAs were
synthesized at Integrated DNA Technologies (IDT), annealed, subcloned into a
lentiviral vector (pLenti6-U6-shRNA-GFP-2A-Puro) (unpublished, K. U. Hong),
and sequence-verified. In pLenti6-U6-shRNA-GFP-2A-Puro vector, the human
U6 small nuclear RNA gene promoter drives the shRNA expression while EGFP
and puromycin resistance gene (pac) are co-expressed under SV40 promoter.
The shRNA lentiviral vectors were then transfected into HEK 293T cells with the
packaging mix to produce lentivirus according to manufacturer’s instructions
(ViraPowerTM Lentiviral Expression System; Invitrogen). The lentivirus-containing
supernatant was harvested and stored in aliquots at -80 °C.

Generating NAT2 overexpression lentivirus
The coding sequences (870 bp) for human NAT2 reference gene (NAT2*4) were
PCR amplified using the following primers: hNAT2 fwd EcoRI, 5’TTTGAATTCATGGACATTGAAGCATATTTTGAAAG-3’ and hNAT2 rev XhoI, 5’TTCTCGAGTAATAGTAAGGGATCCATCACCAGG-3’. The PCR product was
digested with EcoRI and XhoI and subcloned into the pLVX-2xmyc-E2A-PuroT2A-EGFP vector (Unpublished, K. U. Hong), a modified pLVX lentiviral vector
(Clontech), and sequence-verified. The pLVX-2xmyc-E2A-Puro-T2A-EGFP
utilizes viral 2A peptide sequences and allows co-expression of the gene of
interest, plus puromycin resistance gene (pac) and EGFP from the same CMV
promoter. The pLVX NAT2 viral construct was transfected into HEK 293T cells
with the packaging mix to produce lentivirus according to manufacturer’s
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instructions (ViraPowerTM Lentiviral Expression System; Invitrogen). The
lentivirus-containing supernatant was harvested and stored in aliquots at -80 °C.

Lentivirus transduction and selection
HepG2 cells on 6-well plates were transduced with the indicated lentivirus in a
complete media containing 6 μg/ml polybrene. After 2 days, the cells were placed
in complete media containing 2 μg/ml puromycin to select for virus-transduced
cells. The puromycin selection and subsequent passaging of the cells continued
for approximately 2 weeks. Following selection, the cells were examined under a
fluorescent microscope, and as expected, virtually every cell in the culture was
positive for GFP. The cells were then cryo-preserved in 1 ml aliquots in cell
freezing media (90% FBS + 10% DMSO) and stored in liquid nitrogen until use.

Protein quantification and Western blot analysis
HepG2 cells and primary human hepatocytes were lysed with Laemmli buffer (50
mM Tris-Cl [pH 6.8], 2% sodium dodecyl sulfate [SDS; wt/vol], 0.1%
bromophenol blue, 10% [vol/vol] glycerol) and boiled for 10 minutes. Protein
concentrations were determined using Pierce BCA Assay kit (Thermo Scientific)
per manufacturer’s instructions. One to two µL of 2-mercaptoethanol was added
to each sample and boiled again for 5 minutes. Twenty-five to fifty µg of protein
per sample was loaded and separated on 4–12% gradient Bis-Tris Plus
polyacrylamide gels (Invitrogen). The gel was transferred to a PVDF membrane
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and blocked in 5% (w/v) skim milk in tris buffered saline containing 0.1% Tween
20 (TBST) for 30 minutes. Membranes were incubated with primary antibodies
overnight at 4°C. Membranes were washed 3 times for 5 minutes each with
TBST. Membranes were incubated for 1 hour at room temperature with
secondary antibodies. Membranes were washed with TBST 3 times and then
protein was detected with chemiluminescent substrate (Thermo Scientific
Pierce).

Antibodies
The following antibodies were purchased from Cell Signaling: phosphorylatedprotein kinase B (p-AKT S473) #4060 and protein kinase B (AKT) #4691. Αtubulin (clone B-5-1-2) (Sigma-Aldrich) was an additional antibody used as the
control.

Gene Expression
RNA was isolated using E.Z.N.A. Total RNA Kit 1 (OMEGA) per manufacturer’s
protocol. cDNA was synthesized using High Capacity cDNA Reverse
Transcriptase PCR (Thermo Fisher Scientific) per manufacturer’s instructions.
Gene-specific cDNA was quantified with qRT-PCR using self-designed SYBR
Green-based assays. The following primers were designed:
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- glucose-6-phosphatase catalytic subunit (G6PC; forward: 5’ACGAATCTACCTTGCTGCTCA-3’; reverse: 5’-AAAATCCGATGGCGAAGCTG3’)
- phosphoenolpyruvate carboxykinase 1 (PCK1 or PEPCK; forward: 5’TGATGAGCCGCTAGCTTCAG-3’; reverse: 5’-GCCTTTATGTTCTGCAGCCG-3’)
- fatty acid synthase (FASN; forward: 5’-CACACACGATGGACCCTCAG-3’;
reverse: 5’-GAAGAAGGAGAGCCGGTTGG-3’)
-sterol regulatory element binding transcription factor 1 (SREBF1 or SREBP1;
forward: 5’-CACCACCACCGGCGTAG-3’; reverse: 5’GTACCCACTGGCCTTCTCAC-3’).
iTaq Universal SYBR Green Supermix (172–5124, Bio-Rad) was used to perform
qRT-PCR. Reaction conditions were determined per manufacturer’s instructions.

Extracellular Glucose Measurements
Hepatocytes were seeded into Biocoat® collagen coated plates in normal media
conditions for 24 hours to allow attachment. After 24 hours, media was replaced
with complete media containing varying concentrations of HCAs for 2 days.
Then, media was replaced with serum-free, glucose-free media containing
varying concentrations of HCAs for 6 hours. After this completion, media was
replaced in appropriate wells with serum-free, glucose-free media containing
gluconeogenic substrates (2 mM pyruvate, 20 mM lactate, 0.5 mM L-lysine, 5
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mM glycerol) for 24 hours. Finally, the media was collected for extracellular
measurement of glucose and cells were harvested with Laemmli buffer for
protein lysates for normalization to total protein content. Glucose levels were
measured using a glucose (GO) assay kit (Sigma-Aldrich, GAGO-20). Total
protein in each well was measured using the Pierce BCA Assay kit (Thermo
Scientific), and the values were used to normalize the glucose levels.

Statistical analysis
Differences in gene expression among different NAT2 phenotypes and HCA
treatments were tested for significance by One-Way or Two-Way ANOVA
followed by Dunnett’s Multiple Comparison Test or Bonferroni’s Multiple
Comparison Test, respectively. Statistical significance was determined per the
following p-values:
* indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001.
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RESULTS
High-glucose model of insulin resistance in HepG2 cells. We optimized
models that induced insulin resistance in HepG2 cells. Others have reported that
high-glucose and high free fatty acid conditions can induce insulin resistance in
hepatocytes [107, 108]. The high-glucose model here and the high free fatty acid
model discussed later are used in later experiments in combination with
heterocyclic amine (HCA) treatment and varying levels of NAT2 activity to
determine if treatment with HCAs or changes in NAT2 activity can exacerbate
effects of excess nutrient conditions on insulin resistance. To measure changes in
insulin signaling in response to excess nutrients, we cultured HepG2 cells in low
(5.5 mM) or high (25 mM) glucose-containing, serum-free media and then
harvested for protein after 10 minutes of insulin treatment. Western blot was
used to measure induction of p-AKT at the Ser473 site of phosphorylation. As
mentioned previously, phosphorylation of AKT (at Thr308 and Ser473) plays a
key role in the insulin signaling cascade [89]. Thus, we compared p-AKT
(indicating induction of insulin signaling) to total-AKT in a p-AKT/total-AKT ratio.
We found that cells cultured in high glucose conditions had a lower p-AKT
induction (i.e., lower response to insulin) when compared to cells cultured in low
glucose conditions. Consistent with previous reports [107, 108], these results
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(Fig. 5A) indicate that high-glucose condition reduces insulin sensitivity in HepG2
cells.
Additionally, we confirmed our high glucose insulin resistance model by
measuring transcripts of genes involved in gluconeogenesis (glucose-6phosphatase, G6PC; and phosphoenolpyruvate carboxykinase 1, PCK1). HepG2
cells were cultured in low glucose (5.5 mM) or high glucose (25 mM) DMEM for 2
days and then treated with 10 nM insulin for 24 hours. The samples were
harvested for RNA and analyzed by qRT-PCR. Although insulin downregulated
G6PC and PCK1 gene expression in high glucose, relative mRNA levels of both
genes remain upregulated compared to low glucose with insulin (Fig. 5B). Thus,
despite access to excess nutrients, the gluconeogenic gene transcripts are
upregulated in these cells. These results further confirm induction of insulin
resistance in HepG2 cells cultured with high glucose. However, insulin treatment
should have significantly downregulated G6PC and PCK1 in low glucose
conditions. This was not observed and indicates that our insulin treatment was
insufficient. We are optimizing this condition by testing different insulin
concentrations at varying durations of treatment time to improve observed effects
of insulin.
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A.

B.

Figure 5. High glucose model of insulin resistance in HepG2 cells. (A) Cells
were cultured in low glucose (5.5 mM) or high glucose (25 mM) DMEM for 2
days, then serum starved in their respective glucose conditions for 24 hours. We
treated cells with 0, 10, or 100 nM insulin for 10 minutes prior to harvesting cells
for protein. Western blot was used to measure p-AKT (Ser473) and total AKT
levels. (B) Cells were cultured in low glucose (5.5 mM) or high glucose (25 mM)
DMEM for 2 days and then treated with 10 nM insulin for 24 hours. Cells were
then harvested for RNA and analyzed via qRT-PCR. Bars represent mean +/standard error of mean (SEM); n=3.
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High free fatty acid (FFA) model of insulin resistance in HepG2 cells. We
optimized an additional model that induces insulin resistance in HepG2 cells.
Like the high glucose model, this model is used in later experiments in
combination with HCA treatment and varying levels of NAT2 activity to determine
if treatment with HCAs or changes in NAT2 activity can exacerbate effects of
excess nutrient conditions on insulin resistance. To measure changes in insulin
signaling in response to excess FFA, we cultured HepG2 cells in DMEM
containing 1% BSA or varying concentrations of palmitate-BSA (0.125, 0.25, 0.5
mM) for 24 hours, then serum starved them in their respective FFA conditions for
24 hours. We treated cells with 10 nM or 100 nM insulin for 20 minutes prior to
harvesting them for protein. Western blot was used to measure induction of pAKT compared to total-AKT, as previously described. We found that cells
cultured in high FFA conditions had a lower p-AKT induction (i.e. lower response
to insulin) when compared to cells cultured in BSA-only conditions. These results
(Fig. 6A) indicate that high FFA reduces insulin sensitivity in HepG2 cells in a
dose-dependent manner, similarly to results reported by others [108].
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A.

Figure 6. High free fatty acid (FFA) model of insulin resistance in HepG2
cells. (A) We cultured HepG2 cells in DMEM containing 1% BSA or varying
concentrations of palmitate-BSA (0.125, 0.25, 0.5 mM) for 24 hours, then serum
starved them in their respective FFA conditions for 24 hours. We treated cells
with 10 nM or 100 nM insulin for 20 minutes prior to harvesting cells for protein.
Western blot was used to measure p-AKT and total AKT levels.
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Generating shRNA cell lines to knockdown NAT2 in HepG2 cells. NAT2 is a
highly polymorphic gene, and its SNPs produce a variety of phenotypes,
including slow, intermediate, and rapid acetylators. To mimic the NAT2 slow
acetylator phenotype, we generated shRNA NAT2 knockdown in HepG2 cells
using lentiviral vectors. For our studies, we chose the top two candidates
(shRNA4 and shRNA7) of 8 candidates screened. The templates for the
corresponding shRNAs were synthesized, annealed, subcloned into a lentiviral
vector, and sequence-verified. In our vector, the human U6 small nuclear RNA
gene promoter drives the shRNA expression while EGFP and puromycin
resistance gene (pac) are co-expressed under SV40 promoter. Details regarding
transfection are discussed in the Materials and Methods section of the text.
HepG2 cells on 6-well plates were transduced with the lentivirus in a complete
media containing 6 μg/ml polybrene. After 2 days, the cells were placed in
complete media containing 2 µg/ml puromycin to select for virus-transduced
cells. The puromycin selection and subsequent passaging of the cells continued
for approximately 2 weeks. Following selection, the cells were examined under a
fluorescent microscope (Fig. 7A), and as expected, virtually every cell in the
culture was positive for GFP. NAT2 activity was measured in the generated cell
lines as described in the Materials and Methods section, using sulfamethazine
(SMZ) as a substrate to measure in situ activity (Fig. 7B). These results confirm
that the NAT2 activity was successfully knocked down in our HepG2 NAT2
shRNA cell lines.

36

A.

B.

Figure 7. Generation and characterization of HepG2 cell lines stably
expressing control or NAT2 shRNAs. (A) Control and NAT2 shRNA HepG2
cells were examined under a fluorescent microscope following lentiviral
transduction and antibiotics selection. (B) NAT2 activity was measured in situ in
HepG2 shRNA cell lines using SMZ as substrate. Bars represent mean +/standard error of mean (SEM); n=3.
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Generating HepG2 cell lines that overexpress NAT2. NAT2 is a highly
polymorphic gene, and its SNPs produce a variety of phenotypes, including slow,
intermediate, and rapid acetylators. To mimic the NAT2 rapid acetylator
phenotype, we generated HepG2 cell lines that overexpress NAT2 using lentiviral
vectors. Information regarding generation of lentiviral vectors and transfection
can be found in the Methods and Materials section of this text. Cells here were
transduced with lentivirus and selected the same as shRNA cell lines, as
described above. Fig. 8 provides evidence of successful lentivirus-mediated
transduction and upregulation of NAT2 activity measured by acetylation of
sulfamethazine in situ, compared to vector control, although these initial results
show only moderate upregulation of NAT2 activity. Additional cell lines
overexpressing NAT2 were generated by two separate NAT2 clones (NAT2-1
and NAT2-3) that had greater increase in activity (Fig. 9).

38

A.

B.

Figure 8. Generation and characterization of HepG2 cell lines stably
expressing vector or NAT2. (A) We examined HepG2 cells under a fluorescent
microscope following lentiviral transduction. (B) NAT2 activity was measured in
situ in HepG2 cell lines using SMZ as substrate. Bars represent mean +/standard error of mean (SEM); n=3.
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Figure 9. Generation and characterization of additional HepG2 cell lines
stably expressing vector or NAT2. (A) We examined HepG2 cells under a
fluorescent microscope following lentiviral transduction. (B) NAT2 activity was
measured in situ in HepG2 cell lines using SMZ as substrate. ***, p < 0.001. Bars
represent mean +/- standard error of mean (SEM); n=3.
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Significant changes in gluconeogenic and lipogenic gene expression are
observed in HepG2 shRNA knockdown cell lines in low and high glucose
conditions. To investigate the effects of low NAT2 activity on transcripts of
gluconeogenic and lipogenic genes (insulin target genes), we cultured HepG2
NAT2 shRNA cells in low (5.5 mM) and high (25 mM) glucose serum-free media
for one day and then harvested for RNA. As previously described,
gluconeogenesis and lipogenesis are altered with changes in metabolic function
(glucose and lipid production). We measured gluconeogenic (G6PC, PCK1) and
lipogenic (FASN, SREBF1) gene transcripts via qRT-PCR. Even in the absence
of high glucose, gluconeogenic and lipogenic gene expression was
downregulated in NAT2 shRNA cells, compared to control shRNA cells. These
results (Figs. 10 and 11) indicate that NAT2 activity may affect regulation of
glucose and lipid production. Additional experiments incorporating insulin into the
experimental design are required to determine the effect of NAT2 activity on
insulin sensitivity.
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A.

B.

Figure 10. Gluconeogenic gene expression in control and NAT2 shRNA
HepG2 cells (low vs. high glucose). HepG2 shRNA cell lines were cultured in
low glucose (5.5 mM) or high glucose (25 mM) serum-free DMEM conditions for
1 day and harvested for RNA. G6PC and PCK1 levels were measured via qRTPCR. (A) depicts data grouped by glucose treatment and compares control to
NAT2 shRNA4 and shRNA7. (B) depicts data grouped by shRNA cell line and
compares low to high glucose treatment. Statistical significance was determined
by two-way ANOVA followed by Bonferroni’s Posttest; ***, p < 0.001. Bars
represent mean +/- standard error of mean (SEM); n=4.
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A.

B.

Figure 11. Lipogenic gene expression in control and NAT2 shRNA HepG2
cells (low vs. high glucose). HepG2 shRNA cell lines were subjected to low
glucose (5.5 mM) or high glucose (5.5 mM) serum-free DMEM conditions for 1
day and harvested for RNA. FASN and SREBF1 levels were measured via qRTPCR. (A) depicts data grouped by glucose treatment and compares control to
NAT2 shRNA4 and shRNA7. (B) depicts data grouped by shRNA cell line and
compares low to high glucose treatment. Statistical significance was determined
by two-way ANOVA followed by Bonferroni’s Posttest; *, < 0.05, **, p < 0.01, ***,
p < 0.001. Bars represent mean +/- standard error of mean (SEM); n=4.
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Significant changes in gluconeogenic and lipogenic gene expression are
observed in HepG2 shRNA knockdown cell lines in the high FFA model. In
addition to the high glucose model, the previously described high FFA model was
used as a system of insulin resistance with the HepG2 shRNA cells. We cultured
HepG2 shRNA NAT2 knockdown cells in 1% BSA or 0.5 mM palmitate-BSA
serum-free media for one day and then harvested for RNA. We measured
gluconeogenic (G6PC, PCK1) and lipogenic (FASN, SREBF1) gene expression
via qRT-PCR. In response to high FFA, NAT2 shRNA cells showed significant
alterations in the pattern and magnitude of gene expression. The high FFA
treatment downregulated FASN and SREBF1 transcripts in control cells. NAT2
shRNA cells, however, showed increases in expression of the lipogenic genes
under the high FFA condition. In addition, PCK1 mRNA was significantly
upregulated in high FFA-treated NAT2 shRNA cells, while the treatment did not
affect PCK1 expression in control cells. These results (Fig. 12, Fig. 13) suggest
that depletion of NAT2 leads to reductions in glucose and lipid production in
HepG2 cells at both normal and excessive levels of nutrients and that
hepatocytes expressing low NAT2 activity may be less able to effectively respond
to the switch between fed and fasted states. Further investigation of the
dysregulation of gluconeogenic and lipogenic genes in NAT2 knockdown cells
will aid in understanding how NAT2 influences hepatic glucose and lipid
homeostasis. Incorporating insulin into the experimental design will aid in
understanding how changes in NAT2 activity affect insulin sensitivity.
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A.

B.

Figure 12. Gluconeogenic gene expression in control and NAT2 shRNA
HepG2 cells (high FFA model). HepG2 shRNA cell lines were subjected to 1%
BSA or 0.5 mM Palmitate-BSA for 1 day and harvested for RNA. G6PC and
PCK1 levels were measured via qRT-PCR. (A) depicts data grouped by free fatty
acid treatment and compares control to NAT2 shRNA4 and shRNA7. (B) depicts
data grouped by shRNA cell line and compares control (BSA) to high free fatty
acid (PA) treatment. Statistical significance was determined by two-way ANOVA
followed by Bonferroni’s Posttest; **, < 0.01, ***, p < 0.001. Bars represent mean
+/- standard error of mean (SEM); n=4.
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A.

B.

Figure 13. Lipogenic gene expression in control and NAT2 shRNA HepG2
cells (high FFA model). HepG2 shRNA cell lines were subjected to 1% BSA or
0.5 mM Palmitate-BSA for 1 day and harvested for RNA. FASN and SREBF1
levels were measured via qRT-PCR. (A) depicts data grouped by free fatty acid
treatment and compares control to NAT2 shRNA4 and shRNA7. (B) depicts data
grouped by shRNA cell line and compares control (BSA) to high free fatty acid
(PA) treatment. Statistical significance was determined by two-way ANOVA
followed by Bonferroni’s Posttest; *, p < 0.05, **, p < 0.01, ***, p < 0.001. Bars
represent mean +/- standard error of mean (SEM); n=4.
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Cytotoxicity assay was performed in HepG2 cells to determine optimal
concentrations of HCA treatments. We wanted to ensure HCAs would not
result in cell death during experiments, so we tested MeIQ and PhIP, two
common HCAs found in cooked meats [42], at different concentrations in HepG2
cells to detect cell viability. Cells were treated with the indicated compounds at
varying concentrations for 3 days in complete media with no media change
during this time. alamarBlue™ assay was used to measure cell viability. There
was relatively little to no cell death in each of the compounds tested until the
concentration of 100 μM, where nearly half of the cells died in MeIQ (Fig.14).
Moving forward, most experiments used a range of HCA concentrations to
investigate dose-response, and these concentrations ranged from 0 to 100 μM,
although we later switched to ranges from 0 to 50 μM to prevent cell death.
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Figure 14. Cell viability in HepG2 cells after treatment with MeIQ and PhIP.
Cells were treated with either MeIQ or PhIP at concentrations of 0, 0.1, 1.0, 10,
or 100 µM in complete media for 3 days. alamarBlue™ assay was used to
measure cell viability. Bars represent mean +/- standard error of mean (SEM);
n=4.
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No statistically significant change in gluconeogenic or lipogenic gene
expression in HepG2 cells following exposure to PhIP. HCAs are known
human carcinogens and have recently been associated with insulin resistance
and high serum triglycerides [100 – 103]. HCAs are produced when cooking
meats at high temperatures or for long periods of time. Cooking method,
temperature, type of meat, and length of cooking time impact the type of HCA
and level present in the cooked meat [46 – 48], and this is further described in
previous sections of this text. PhIP is the most common HCA found in cooked
meats, though it is less genotoxic compared to other HCAs [44, 109]. To
investigate if exposure to PhIP impacts gluconeogenic or lipogenic gene
expression, we cultured HepG2 cells in low-glucose or high-glucose media
containing PhIP at varying concentrations (0 – 100 μM) for 3 days and then
harvested for RNA. The samples were analyzed by qRT-PCR to measure
transcripts of genes involved in gluconeogenesis and lipogenesis. There were no
statistically significant changes observed in gluconeogenic (G6PC, PCK1) or
lipogenic (FASN, SREBF1) gene expression following exposure to PhIP at any
concentration in either low glucose or high glucose conditions. These results
(Fig. 15) suggest that PhIP has little impact on regulation of glucose and lipid
production in hepatocytes.
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Figure 15. Gluconeogenic and lipogenic gene expression in HepG2 cells
following PhIP treatment. HepG2 cells were cultured in low glucose (5.5 mM)
or high glucose (25 mM) DMEM and DMSO or varying concentrations (0, 1, 10 or
100 µM) of PhIP for 3 days and then harvested for RNA. Samples were analyzed
with qRT-PCR. Statistical significance was determined by one-way ANOVA. Bars
represent mean +/- standard error of mean (SEM); n=4.
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Gluconeogenic and lipogenic gene expression in HepG2 cells is
dysregulated by exposure to particular HCAs. To investigate the effects of
HCAs on gluconeogenic and lipogenic gene transcription, we screened a variety
of HCAs, including MeIQ, MeIQx, IQ, and IQx, as these are some additional
common HCAs found in cooked meats. We cultured HepG2 cells with each HCA
for 3 days and then harvested for RNA. The samples were analyzed by qRTPCR to measure transcripts of genes involved in gluconeogenesis and
lipogenesis. We observed a variety of results among the different HCAs. G6PC
was upregulated in MeIQx, while G6PC and SREBF1 were downregulated in IQ
and IQx. There were no statistically significant changes in FASN among any of
the HCAs screened compared to the control group (Fig. 16). This variety of
results led us to believe that metabolic processes (glucose and lipid production)
are dysregulated by HCAs, but it is currently unclear how and what is causing the
differences in dysregulation among varying HCAs. Additionally, HepG2 cells may
already exhibit irregular metabolic function because they are a transformed cell
line [124]. This led to further investigation of MeIQ and MeIQ-like compounds in
primary human hepatocytes, discussed later in this text.
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Figure 16. Gluconeogenic and lipogenic gene expression in HepG2 cells
following HCA treatment. HepG2 cells were cultured in low glucose (5.5 mM)
DMEM and DMSO or varying concentrations (5 or 50 µM) of MeIQ, MeIQx, IQ, or
IQx for 3 days and then harvested for RNA. Samples were analyzed with qRTPCR. Statistical significance was determined by one-way ANOVA followed by
Dunnett’s Multiple Comparison Test; *, p < 0.05, **, p < 0.01. Bars represent
mean +/- standard error of mean (SEM); n=4.
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Dysregulation of gluconeogenic and lipogenic gene expression in HepG2
cells in low glucose conditions following MeIQ exposure is further
analyzed. Since the previous experiment screening several HCAs had high
variability within experimental groups, we repeated the experiment with additional
concentrations of MeIQ to analyze if exposure to MeIQ altered transcripts of
G6PC, PCK1, FASN, and SREBF1. We cultured HepG2 cells in low glucose
DMEM containing MeIQ at varying concentrations (0 – 100 µM) for 3 days and
then harvested for RNA. The samples were analyzed by qRT-PCR to measure
transcripts of genes involved in gluconeogenesis and lipogenesis. G6PC, PCK1,
and FASN were significantly upregulated following MeIQ exposure. In contrast,
SREBF1 was not significantly altered by MeIQ exposure. These results suggest
MeIQ may directly impact steady-state glucose and lipid production in
hepatocytes, although insulin treatment must be incorporated into the
experimental design to measure alterations in insulin sensitivity. The statistical
significance found in this experiment that was not apparent in the results from
Figure 17 can likely be accredited to reduced variability within groups in the
current experiment.
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Figure 17. Gluconeogenic and lipogenic gene expression in HepG2 cells
following MeIQ treatment. HepG2 cells were cultured in low glucose (5.5 mM)
DMEM and DMSO or varying concentrations (0, 1, 10 or 100 µM) of MeIQ for 3
days and then harvested for RNA. Samples were analyzed with qRT-PCR.
Statistical significance was determined by one-way ANOVA followed by
Dunnett’s Multiple Comparison Test; *, p < 0.05, **, p < 0.01. Bars represent
mean +/- standard error of mean (SEM); n=4.
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Changes in gluconeogenic and lipogenic gene expression in HepG2 cells
following MeIQ exposure is not observed in the high glucose model. To
investigate effects of MeIQ exposure on gluconeogenic and lipogenic gene
expression in the presence of excess nutrients, we cultured HepG2 cells in high
glucose DMEM containing MeIQ at varying concentrations (0 – 100 µM) for 3
days and then harvested for RNA. The samples were analyzed by qRT-PCR to
measure transcripts of genes involved in gluconeogenesis and lipogenesis. The
changes in gene expression previously observed are no longer present in the
high glucose model. The excess nutrients appear to overcome the previously
observed effects of MeIQ. These results (Fig. 18) suggest that dysregulation of
glucose and lipid production resulting from excess glucose supersede the effects
of MeIQ observed in normal nutrient conditions, resulting in no significant
changes among varying MeIQ treatment concentrations.
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Figure 18. Gluconeogenic and lipogenic gene expression in HepG2 cells
following MeIQ treatment. HepG2 cells were cultured in high glucose (25 mM)
DMEM and DMSO or varying concentrations (1, 10 or 100 µM) of MeIQ for 3
days and then harvested for RNA. Samples were analyzed with qRT-PCR.
Statistical significance was determined by one-way ANOVA. Bars represent
mean +/- standard error of mean (SEM); n=4.
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MeIQ exposure significantly upregulates gluconeogenic gene transcripts
and significantly downregulates lipogenic gene transcripts in primary
human hepatocytes. In addition to HepG2 cells, we investigated the effects of
HCAs on gluconeogenic and lipogenic gene transcripts in primary human
hepatocytes, as these are more physiologically relevant and have relatively
normal metabolic function (compared to HepG2 cells, which are transformed
cancer cells). We cultured primary human hepatocytes in high glucose DMEM
containing 0, 5, or 50 µM MeIQ for 3 days and then harvested for RNA. These
samples were analyzed via qRT-PCR. G6PC and PCK1 gene transcripts were
upregulated significantly in 5 and 50 µM MeIQ compared to the control (DMSO).
Additionally, FASN and SREBF1 gene transcripts were significantly
downregulated in 50 µM MeIQ. These results (Fig. 19) suggest that MeIQ
exposure affects gluconeogenic and lipogenic gene transcript levels also in
primary human hepatocytes. We will need to introduce insulin into the
experimental design to examine if MeIQ affects sensitivity to insulin.
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Figure 19. Gluconeogenic and lipogenic gene expression in primary
hepatocytes following MeIQ treatment. Primary human hepatocytes were
cultured in high glucose (25 mM) DMEM with 0, 5, or 50 µM MeIQ for 3 days and
then harvested for RNA. Samples were analyzed by qRT-PCR. Statistical
significance was determined by one-way ANOVA followed by Tukey’s Multiple
Comparison Test; *, p < 0.05, ***, p < 0.001. Bars represent mean +/- standard
error of mean (SEM); n=4.
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Insulin-induced p-AKT is reduced by MeIQ exposure in primary human
hepatocytes. Although there was a significant difference in gluconeogenic and
lipogenic gene transcription in primary human hepatocytes following MeIQ
exposure, we wanted to determine if MeIQ exposure alters insulin signaling as
well. We analyzed the effects of MeIQ on primary human hepatocytes via p-AKT
induction (by insulin) on Western blot. Primary human hepatocytes were cultured
with 0, 5, or 50 µM MeIQ in complete media for 2 days, then serum-starved for
24 hours (still with MeIQ treatment in serum-free media). Hepatocytes were then
treated with 100 nM insulin for 10 minutes. There was an apparent reduction in pAKT induction in response to insulin in cells treated with MeIQ (Fig. 20). These
results suggest that MeIQ reduces insulin sensitivity in primary human
hepatocytes.
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Figure 20. Insulin-induced p-AKT following MeIQ treatment in primary
hepatocytes. Primary human hepatocytes were cultured with 0, 5, or 50 µM
MeIQ in complete media for 2 days. Hepatocytes were serum-starved with MeIQ
treatment for 24 hours. Hepatocytes were then treated with 100 nM insulin for 10
minutes then harvested for protein. Samples were analyzed via Western blot to
measure induction of p-AKT.
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No change in glucose production is observed in primary hepatocytes
following MeIQ treatment. Since we observed changes in gluconeogenic gene
expression and insulin signaling in primary hepatocytes following MeIQ
treatment, we chose to examine if MeIQ treatment altered glucose production in
primary hepatocytes. Hepatocytes were treated with complete media containing
varying concentrations of MeIQ for 2 days. Then, media was replaced with
serum-free, glucose-free media containing varying concentrations of MeIQ for 6
hours. After completion of this period, media was replaced with serum-free,
glucose-free media containing gluconeogenic substrates (2 mM pyruvate, 20 mM
lactate, 0.5 mM lysine, 5 mM glycerol) for 24 hours. Finally, the media was
collected for extracellular measurement of glucose (via glucose oxidase (GO)
assay kit), and cells were harvested for normalization to total protein. There was
no detectable change in glucose production following treatment with MeIQ (Fig.
21).
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Figure 21. Glucose production in primary hepatocytes following MeIQ
treatment. Primary human hepatocytes were cultured in complete media
containing 0, 5, or 50 µM MeIQ for 2 days. Media was replaced with serum-free,
glucose-free media containing respective concentrations of MeIQ for 6 hours.
Media was replaced in appropriate wells with serum-free, glucose-free media
containing gluconeogenic substrates (2 mM pyruvate, 20 mM lactate, 0.5 mM
lysine, 5 mM glycerol) for 24 hours. Media was collected for extracellular glucose
measurements via a glucose oxidase (GO) assay kit, and cells were harvested
for total protein measurements. Bars represent mean +/- standard error of mean
(SEM); n=4.
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DISCUSSION
There have been recently documented associations between dietary
heterocyclic amine (HCA) intake and insulin resistance and between Nacetyltransferase 2 (NAT2) polymorphisms and insulin resistance [111, 112].
However, the association between dietary HCA intake and pathogenesis of
insulin resistance has yet to be confirmed or directly investigated, and it is
currently unclear the role of NAT2-mediated metabolism in this process. The
current study investigates the effects of HCA and NAT2 phenotypes on insulin
sensitivity and expression levels of genes involved in glucose and lipid
metabolism in hepatocytes of human origin, including HepG2 (hepatocellular
carcinoma) cells and cryopreserved human primary hepatocytes. Dysregulation
of glucose and lipid production was observed in HepG2 NAT2 shRNA cell lines in
both normal and excess nutrient conditions (Figs. 10 – 13), suggesting that NAT2
activity levels may directly play a role in glucose and lipid homeostasis in
hepatocytes. MeIQ, a common HCA found in cooked meat, also altered levels of
mRNA gene transcripts of genes involved in gluconeogenesis and lipogenesis
and reduced insulin signaling, suggesting that MeIQ may directly impact steadystate glucose and lipid production and reduce insulin sensitivity in hepatocytes,
although no changes in glucose production were observed in response to MeIQ
treatment.
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HepG2 NAT2 shRNA cell lines and measuring transcripts of insulin-target
genes
Recently, certain genetic polymorphisms of NAT2 have been linked to
insulin resistance, high serum triglyceride, coronary artery disease, and high
fasting plasma glucose level [112 – 116]. Analysis of Nat1-knockout (homolog of
human NAT2) mice revealed that Nat1 deficiency leads to development of insulin
resistance and metabolic defects at the systemic level, supporting the previously
unrecognized role of NAT2 in regulating metabolism and insulin sensitivity [117 –
118]. However, it is currently unknown how NAT2 influences cellular metabolism
and insulin sensitivity.
In the current study, dysregulation of genes involved in glucose and lipid
metabolism was observed in HepG2 NAT2 shRNA cell lines in both normal and
excess nutrient conditions (high glucose and high free fatty acid) (Figs. 10-13). A
significant reduction (p < 0.001) in transcripts of genes involved in
gluconeogenesis (G6PC, PCK1) and lipogenesis (FASN, SREBF1) was detected
in both NAT2 shRNA cell lines (shRNA4 and shRNA7) in low and high glucose
conditions (Fig. 10, Fig. 11), indicating that the presence of excess nutrients was
not required for alterations in mRNA transcript levels, but rather reduced NAT2
activity caused the difference observed.
The high FFA treatment, in contrast, downregulated FASN and SREBF1
transcripts in control cells. NAT2 shRNA cells, however, showed increases in
expression of the lipogenic genes under the high FFA condition. In addition,
PCK1 mRNA was significantly upregulated in high FFA-treated NAT2 shRNA
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cells, while the treatment did not affect PCK1 expression in control cells. These
results (Figs. 12 – 13) suggest that depletion of NAT2 leads to reduction in
glucose and lipid metabolism in HepG2 cells at both normal and excessive levels
of nutrients and that hepatocytes expressing low NAT2 activity may be less able
to effectively respond to the switch between fed and fasted states. Further
investigation of the dysregulation of gluconeogenic and lipogenic genes in NAT2
knockdown cells will aid in understanding how NAT2 influences hepatic glucose
and lipid homeostasis. Incorporating insulin into the experimental design will aid
in understanding how changes in NAT2 activity affect insulin sensitivity.
Additionally, utilizing cryopreserved primary human hepatocytes with naturally
occurring slow, intermediate, or rapid NAT2 acetylator phenotypes will provide a
more physiologically relevant model for these experiments and translation of the
results to human populations.

PhIP treatment on HepG2 cells and measuring transcripts of insulin-target
genes
HCAs are produced when cooking meats at high temperatures or for long
periods of time. Cooking method, temperature, type of meat, and length of
cooking time impact the type of HCA and level present in the cooked meat [46 –
48]. 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) is a common HCA
found in cooked meats, though it is less genotoxic compared to other HCAs [44,
109]. Though we do not know if genotoxicity of HCAs is linked to their
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hypothesized effect on insulin sensitivity, we chose to utilize PhIP for initial
experiments since it is the most common HCA found in cooked meat.
In the current study, there were no statistically significant changes
observed in gluconeogenic (G6PC, PCK1) or lipogenic (FASN, SREBF1) gene
expression following exposure to PhIP at any concentration in either low glucose
or high glucose conditions. These results (Fig. 15) suggest that PhIP may have
little impact on regulation of insulin-target genes in hepatocytes. Additionally,
previous studies investigating carcinogenic potential of HCAs largely focused on
MeIQ and MeIQ-like compounds because they are more genotoxic in mammalian
cells [38]. Thus. we chose to focus future experiments in this study on MeIQ and
MeIQ-like compounds.

Screening of treatment with different HCAs on HepG2 cells and measuring
transcripts of insulin-target genes
Several different HCAs are found in cooked meats, and the type of HCA
and their concentrations vary depending on cooking method, temperature, type
of meat, and length of cooking time [46 – 48]. Since no changes in transcript
levels of insulin-target genes were observed with PhIP treatment in HepG2 cells,
we aimed to screen additional HCAs for future experiments. 2-amino-3methylimidazo[4,5-ƒ]quinoline (IQ); and 2-amino-3,4-dimethylimidazo[4,5ƒ]quinoline (MeIQ); and their structurally related compounds 2-amino-3methylimidazo[4,5-f]quinoxaline (IQx); and 2-amino-3,8-dimethylimidazo[4,5-
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f]quinoxaline (8-MeIQx) were screened next, as these are additional HCAs
frequently found in cooked meat [49 – 53].
In this experiment, we observed a variety of results among the different
HCAs (Fig. 16). G6PC was upregulated in MeIQx, while G6PC and SREBF1
were downregulated in IQ and IQx, compared to control treatment. There were
no statistically significant changes in FASN levels among any of the HCAs
screened compared to the control group. This variety of results led us to believe
that metabolic processes (glucose and lipid production) are dysregulated by
HCAs, but it is currently unclear how and what is causing the differences in
dysregulation among varying HCAs.
As the mechanisms by which HCAs alter insulin-target gene transcription
remains unknown, structural differences among different HCAs may account for
differences observed in this study [123]. Additionally, HepG2 cells may already
exhibit irregular metabolic function because they are an immortalized cell line
[124], and thus it is unclear if some differences seen in this study are the result of
HepG2 model system. Moreover, we conducted experiments with MeIQ and
MeIQ-like compounds in primary human hepatocytes to account for potential
irregularities in HepG2 cellular metabolic function.
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MeIQ treatment on HepG2 cells and measuring transcripts of insulin target
genes
As previously mentioned, MeIQ and MeIQ-like compounds are HCAs
frequently found in cooked meat [49 – 53]. Our previous study (Fig. 16) indicated
that gluconeogenic and lipogenic gene transcripts were dysregulated with some
of the compounds in this structural group of HCAs, so we investigated this
phenomenon further.
In this study, G6PC, PCK1, and FASN transcripts were significantly
upregulated following MeIQ exposure. In contrast, SREBF1 was not significantly
altered by MeIQ exposure (Fig. 17). These results suggest MeIQ may impact
steady-state glucose and lipid production in hepatocytes, although insulin
treatment must be incorporated into the experimental design to measure
alterations in insulin sensitivity. The statistical significance found in this
experiment that was not apparent in the results from Figure 16 can likely be
accredited to reduced variability within experimental groups in the current
experiment.
We additionally incorporated our previously characterized high glucose
model (Fig. 5) into our experiment with MeIQ treatment on HepG2 cells to
evaluate if excess nutrient conditions further exacerbated the effects observed in
normal nutrient conditions. In this study, the changes in gene expression
previously observed (Fig. 17) are no longer present in the high glucose model
conditions. The excess glucose appears to abolish the previously observed
effects of MeIQ, resulting in no change between the MeIQ-treated groups and
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control groups. Another consideration is that if both high glucose and MeIQ use
the same pathway to induce gluconeogenic genes, then additive or synergistic
effects may not be observed. These results (Fig. 18) suggest that dysregulation
of glucose and lipid metabolism resulting from excess glucose supersede the
effects of MeIQ treatment observed in normal nutrient conditions, resulting in no
significant changes among varying MeIQ treatment concentrations, compared to
control. It is unclear at this time why effects of MeIQ treatment observed in low
glucose conditions are not present in high glucose conditions. However, we need
to incorporate insulin treatment into our experimental design to measure changes
in mRNA transcripts in response to insulin to further investigate this observation.

MeIQ treatment on cryopreserved human primary hepatocytes and
measuring transcripts of insulin-target genes
MeIQ treatment on HepG2 cells significantly changed mRNA levels of
insulin target gene transcripts (Fig. 17). However, as previously mentioned,
HepG2 cells are immortalized and thus may exhibit irregularities in metabolic
function and glucose and lipid homeostasis [124]. Thus, we chose to additionally
investigate effects of MeIQ treatment in cryopreserved human primary
hepatocytes.
In this study, G6PC and PCK1 gene transcripts were upregulated
significantly following treatment with 5 and 50 µM MeIQ compared to the control
(DMSO). Additionally, FASN and SREBF1 gene transcripts were significantly
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downregulated following treatment with 50 µM MeIQ. These results (Fig. 19)
suggest that MeIQ alters gluconeogenic and lipogenic gene transcription in
primary human hepatocytes, similarly to the effects observed in HepG2 cells.
Again, we will need to introduce insulin into the experimental design to examine if
MeIQ affects sensitivity to insulin. However, these results indicate a change in
glucose and lipid homeostasis induced by treatment of MeIQ, further validating
the previously observed phenomenon.

MeIQ treatment on cryopreserved human primary hepatocytes and
measuring p-AKT induction as an indicator of insulin sensitivity
MeIQ treatment significantly altered gluconeogenic and lipogenic gene
transcript levels in human primary hepatocytes (Fig. 19). However, changes in
mRNA transcripts of gluconeogenic and lipogenic genes is not adequate to
determine insulin sensitivity. We followed up by incorporating insulin into the
experimental design and measuring insulin-mediated induction of p-AKT, a key
component of the insulin cascade, which is discussed in detail in the Background
portion of this text (Fig.4).
In this study, there was an apparent reduction in p-AKT induction in
response to insulin in cells treated with MeIQ (Fig. 20). These results suggest
that MeIQ induces insulin resistance in primary human hepatocytes. However,
these results do not indicate if there is a change in glucose production in
response to insulin following treatment of MeIQ. Thus, a glucose production
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assay is needed to measure the ultimate physiological effect of insulin
resistance.

MeIQ treatment on cryopreserved human primary hepatocytes and
measuring glucose production
MeIQ treatment on HepG2 cells significantly changed mRNA levels of
gene transcripts involved in insulin signaling (Fig. 17), and there was an apparent
reduction in p-AKT induction in response to insulin in cells treated with MeIQ
(Fig. 20). However, neither of these endpoint measurements indicate if MeIQ
treatment results in a change of glucose production in response to insulin. Thus,
we utilized a glucose production assay to measure extracellular glucose
concentrations in response to insulin following treatment with MeIQ.
In this study, there was no detectable change in glucose production
following treatment with MeIQ (Fig. 21). It is currently unclear as to why changes
in gluconeogenic gene transcripts verified by a reduction in insulin signaling did
not translate into changes in glucose production. However, this experiment still
needs to be repeated to ensure reproducibility. Additionally, insulin must be
incorporated into the experimental design to determine changes in glucose
production in response to insulin treatment following MeIQ treatment.
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CONCLUSIONS AND SUMMARY
Strengths of work
Recently, NAT2 polymorphisms have been linked to insulin resistance,
high serum triglyceride levels, coronary artery disease, and high fasting plasma
glucose level [112 – 116]. A deficiency of mouse Nat1 leads to development of
insulin resistance and metabolic defects in Nat1-knockout mice [117, 118].
However, thus far, all studies on this link have been conducted in murine
systems. Using Nat1 KO mice as a surrogate for studying the effects of human
NAT2 presents major limitations. As previously reviewed [125], the mouse Nat1
coding sequence is only slightly more homologous to human NAT2 than to
human NAT1, and for amino acid homology, mouse Nat1 is actually more
homologous to human NAT1 (73%) than human NAT2 (72%). Mouse Nat1 is
much less stable than human NAT2 [125]. Mouse Nat1 is expressed across
every tissue examined [126], whereas human NAT2 expression is largely limited
to liver and GI tract. Additionally, the substrate profiles of mouse Nat1 and
human NAT2 are less similar than previously believed [127]. Therefore, it is likely
that mouse Nat1 and human NAT2 do not share identical roles. Also, the findings
obtained from Nat1 KO mice are limited by the fact that human NAT2 alleles that
were reported to be linked to insulin resistance, as well as coronary artery
disease and high triglyceride levels, are not null but functional alleles [116].
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Therefore, murine models of Nat1 biology may not accurately reflect the role of
human NAT2 in insulin resistance. The present study utilizes human cell systems
(HepG2 NAT2 shRNA cell lines) that mimic the conditions created by different
NAT2 alleles. Thus, this study may provide a more clinically relevant depiction of
the effects of NAT2 activity on insulin sensitivity in humans.
Additionally, a significant association was recently reported between HCA
exposure via cooked meat consumption and insulin resistance after the
multivariate analysis was adjusted for saturated fatty acid and cholesterol intake
[111]. However, this association has yet to be confirmed in cell or animal models.
There was a lack of laboratory studies entirely on this alleged link. Thus, this
study reports the first findings in associations between HCA exposure and insulin
resistance in a cell culture model.
Our results indicate that both level of NAT2 activity and exposure to
certain HCAs may alter cellular glucose and lipid homeostasis. Additionally,
these results demonstrate changes in sensitivity to insulin following exposure to
some HCAs. These findings are significant because they indicate a genetic
component (NAT2 polymorphism) and an environmental component (dietary
HCA exposure via consumption in cooked meat) in the pathogenesis of insulin
resistance in hepatocytes of human origin. As insulin resistance is a key
component of type II diabetes mellitus and metabolic syndrome [71 – 73], these
findings pose a significant contribution to public health.
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Limitations of work
The present study utilizes human cell systems (HepG2 NAT2 shRNA cell
lines) that mimic slow acetylator NAT2 phenotype. However, additional studies
must be conducted using HepG2 cells overexpressing NAT2, which serve to
mimic rapid acetylator NAT2 phenotype. Moreover, as previously mentioned,
HepG2 cells are immortalized and may not represent a physiologically accurate
model of “normal” energy homeostasis. HepG2 cells also have naturally low
NAT2 expression. To account for this, cryopreserved human primary hepatocytes
that have been genotyped and grouped by rapid, intermediate, or slow NAT2
acetylator phenotype should be used to confirm findings from experiments
conducted with HepG2 cells.
Additionally, this study reports this first findings in associations between
HCA exposure and insulin resistance in a cell culture model. However, several
experiments presented here need to be repeated with insulin treatment
incorporated into the experimental design so that changes in response to insulin
may be measured. Furthermore, associations between HCA exposure and
insulin resistance have yet to be investigated in animal models. MeIQx, the
second most abundant HCA found in cooked meat [47], has been shown to
cause liver tumors in animal models [128]. A previous study reported that oral
administration of MeIQx (0.06% in food pellet) for 84 weeks in CDF1 mice
resulted in increased frequency of hepatocellular carcinoma in male and female
mice [128]. Similar animal models to those investigating carcinogenesis and HCA
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exposure in mice can be applied to the studies here to analyze endpoints relating
to insulin signaling and insulin sensitivity.
Lastly, and most importantly, these studies have not yet incorporated both
NAT2 polymorphism and HCA treatment into one experimental design. The
major metabolic pathway of HCAs includes hepatic N‑hydroxylation by CYP1A2
followed by O-acetylation by NAT2 to form reactive oxygen species (ROS)
leading to oxidation of lipids, proteins, and nucleic acids [129, 130]. Future
studies should investigate both the novel link between HCA exposure to the
development of insulin resistance and the role of NAT2-mediated metabolism in
this process to consider a gene-environmental interaction.
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May 2019

HONORS, AWARDS, CERTIFICATIONS
IPIBS Fellowship (full tuition and stipend)
2019 - 2021
Awarded by the University of Louisville upon admittance as a graduate student to
the Department of Pharmacology and Toxicology
Rachel Davis Memorial Scholarship Recipient
2019
Awarded by the Rachel Davis Memorial Scholarship Endowment Chair for
displaying exceptional stewardship in environmental extracurriculars; monetary
award
University of Louisville Cancer Education Program Trainee
2018
Participant in the 10-week summer Cancer Education Program, a competitive
program funded by the National Institute of Health; aims to train the next
generation of cancer researchers
University of Louisville Undergraduate Research Grant
2018
Awarded by the University of Louisville to sponsor undergraduate research and
poster presentation
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Pharmacy Technician Certification
2017
Awarded by the National Healthcare Association upon passing the Exam of the
Certified Pharmacy Technicians (ExCPT)
Speed School Academic Affairs Scholarship
2016
Awarded by the J.B. Speed School of Engineering Academic Affairs Committee
for displaying academic excellence; monetary award to assist in paying for study
abroad
P.E.O. STAR Scholarship Recipient
2015
Awarded by the national P.E.O chapter for exhibiting excellence in leadership,
academics, extracurricular activities, community service and potential for future
success; monetary award for higher education
Kentucky Governor’s Scholar
2014
Participant in the Kentucky Governor's Scholars Program, a highly competitive
summer program which provides opportunity for academic and personal growth

RESEARCH EXPERIENCE
University of Louisville, Department of Pharmacology and Toxicology 2019 –
present
Graduate fellow, Hein Lab
• Determining effects of NAT2 genetic polymorphism on insulin sensitivity
• Evaluating impacts of HCAs on insulin resistance
• Investigating the role of NAT2-mediated metabolism of HCAs in
pathogenesis of insulin resistance
University of Louisville, Department of Microbiology and Immunology
2019
Research Scientist, Sokoloski Lab
• Selecting for viral revertants by serial passaging the existing SINV nsP1
mutants until genetic reversion was observed via a change in viral kinetics
or an oblique alteration of virus phenotype
• Identifying the genetic basis of the reversion event(s) using nextgeneration sequencing technologies to map the amino acid changes with
respect to time
• Biochemically and biologically assessing the revertants by using sitedirected mutagenesis to recapitulate the observed amino acid changes in
a clean genetic background to evaluate the impact of the reversion events
on viral RNA synthesis and viral capping kinetics in tissue culture models
of infection
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Cancer Education Program, Department of Pharmacology and Toxicology 2018
Research Scientist, Siskind Lab
• Determining the effects on renal function of using erlotinib as an injuryameliorating agent following the completion of the clinically relevant CDDP
repeated dosing model
• Executing lab techniques including PCR, Western Blot analysis, IHC to
collect data in an independent study
University of Louisville, Department of Pharmacology and Toxicology
2018
Research Scientist, Siskind Lab
• Utilizing a clinically relevant mouse model of cisplatin-induced kidney
injury
• Determining the effects on renal function of using erlotinib, an EGFR
inhibitor, in combination with cisplatin

PRESENTATIONS
American Society of Pharmacology and Experimental Therapeutics
April 2021
Department of Pharmacology and Toxicology
“Changes in Insulin Signaling and Gluconeogenic Gene Expression in Human
Hepatocytes Following Exposure to Heterocyclic Amines”
Graduate Student Regional Research Conference, virtual
February 2021
Department of Pharmacology and Toxicology
“Changes in Insulin Signaling and Gluconeogenic Gene Expression in Human
Hepatocytes Following Heterocyclic Amine Treatment”
Ohio Valley Society of Toxicology Annual Meeting, virtual
November 2020
Department of Pharmacology and Toxicology
“Depletion of arylamine N-acetyltransferase 2 results in dysregulation of
gluconeogenic and lipogenic genes in HepG2 hepatocellular carcinoma cell line”
UofL Pharmacology and Toxicology Dept. Seminar, virtual
April 2020
Department of Pharmacology and Toxicology
“Heterocyclic Amines and Arylamine N-Acetyltransferase 2 Polymorphism in
Insulin Resistance”
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ACC Meeting of the Minds, Louisville, KY
March 2019
Department of Pharmacology and Toxicology
“Repeated administration of cisplatin increases EGFR/EGFR activation and renal
fibrosis in Kras4bG12D lung adenocarcinoma-bearing mice, but kidney injury is
further exacerbated with erlotinib/cisplatin combination treatment”
Posters at the Capitol, Frankfort, KY
February 2019
Department of Pharmacology and Toxicology
“Repeated administration of cisplatin increases EGFR/EGFR activation and renal
fibrosis in Kras4bG12D lung adenocarcinoma-bearing mice, but kidney injury is
further exacerbated with erlotinib/cisplatin combination treatment”
Research!Louisville Poster Presentation, Louisville, KY
October 2018
Department of Pharmacology and Toxicology
“Repeated administration of cisplatin increases EGFR/EGFR activation and renal
fibrosis in Kras4bG12D lung adenocarcinoma-bearing mice, but kidney injury is
further exacerbated with erlotinib/cisplatin combination treatment”
Cancer Education Program Poster Presentation, Louisville, KY
August 2018
Department of Pharmacology and Toxicology
“Repeated administration of cisplatin increases EGFR/EGFR activation and renal
fibrosis in Kras4bG12D lung adenocarcinoma-bearing mice, but kidney injury is
further exacerbated with erlotinib/cisplatin combination treatment”
University of Louisville Undergraduate Research Symposium
April 2018
Department of Pharmacology and Toxicology
“Repeated administration of cisplatin increases EGFR/EGFR activation and renal
fibrosis in Kras4bG12D lung adenocarcinoma-bearing mice, but kidney injury is
further exacerbated with erlotinib/cisplatin combination treatment”

PEER REVIEWED PUBLICATIONS
Hong, K. U., Doll, M. A., Lykoudi, A., Salazar-González, R. A., Habil, M. R.,
Walls, K. M., . . . Hein, D. W. (2020). Acetylator Genotype-Dependent
Dyslipidemia in Rats Congenic for N-Acetyltransferase 2. Toxicology Reports.
doi:10.1016/j.toxrep.2020.09.011
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WORK EXPERIENCE
Walmart Pharmacy
Certified Pharmacy Technician

2016-2019

PROFESSIONAL TRAINING
Graduate Student Regional Research Conference
Virtual, 2021
Attended virtually and presented orally; viewed oral and poster presentations
Ohio Valley Society of Toxicology Annual Meeting
Virtual, 2020
Attended virtually and presented poster; viewed oral and poster presentations
ACC Meeting of the Minds Annual Conference
Louisville, KY 2019
Attended and presented research poster; participated in networking and
professional development seminars
Society of Women Engineers Annual Conference
Nashville, TN 2015
Attended and participated in networking and professional development seminars

PROFESSIONAL AFFILIATIONS
American Society of Pharmacology and Experimental Therapeutics, 2020present
Society of Toxicology, 2020-present
Society of Undergraduate Chemistry Students, 2016-2019
Society of Women Engineers, 2015-2019
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PROFESSIONAL SERVICE
University of Louisville Undergraduate Peer Mentor Host
2015-2019
Provide campus tours to prospective chemistry students at the University of
Louisville
VESA Student Helper
2018-2019
Assist in distributing material to University of Louisville students about the
Volunteer Eco Students Abroad program
Present orally about VESA experience to prospective students
GREEN Program On-Campus Ambassador
2017-2018
Lead a recruitment campaign on the University of Louisville campus for the
GREEN study abroad program
Create and distribute marketing materials to provide information to students
Present orally at club meetings and relevant classrooms about the program

SERVICE ABROAD
Volunteer Eco Students Abroad
Volunteer, South Africa, May 2018
Volunteer focus in conservation, education, and construction
Built a watering hole at St. Lucia Crocodile Center, cleaned pens of savannah
cats at The Emdoneni Cheetah Project
Taught mathematics/English at local school in the Zulu Village, prepared lunches
at local orphanage
Built the foundation of a home gifted to a local family of 9 deemed in dire need of
assistance
Elephant Haven
Volunteer, Thailand, July-August 2017
Offered time and compassion to feed and bathe elephants in a sanctuary setting
during the rehabilitation process

EDUCATIONAL TRAVEL
Reykjavik University Iceland School of Energy
Studied geothermal energy, hydroelectric energy, energy economics
Toured clean energy facilities
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